WAY-214156

In this article, we will explore various aspects related to WAY-214156, delving into its importance and relevance in different contexts. Along these lines, we will analyze its impact and influence on contemporary society, as well as its evolution over time. In addition, we will examine the different perspectives and opinions that exist around WAY-214156, with the aim of offering a broad and complete vision on this topic. From its origins to its current state, this article will approach WAY-214156 from multiple angles, providing the reader with a comprehensive and enriching understanding of it. Without a doubt, this is a fascinating topic that deserves to be explored in detail.

WAY-214156
Identifiers
  • 2,8-Dihydroxy-6H-dibenzochromene-4,12-dicarbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC19H10N2O3
Molar mass314.300 g·mol−1
3D model (JSmol)
  • C1C2=C(C=CC(=C2)O)C3=C(O1)C4=C(C=C(C=C4C#N)O)C(=C3)C#N
  • InChI=1S/C19H10N2O3/c20-7-10-5-17-15-2-1-13(22)4-12(15)9-24-19(17)18-11(8-21)3-14(23)6-16(10)18/h1-6,22-23H,9H2
  • Key:UGZYFAJTTRGNOX-UHFFFAOYSA-N

WAY-214156 is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.[1][2] It is 100-fold selective for the ERβ over the ERα with an IC50 of 4.2 nM (compare to estradiol with IC50 values of ~3–4 nM for both the ERα and ERβ).[1] The drug is less selective for the ERβ than is prinaberel (ERB-041, WAY-202041), another selective ERβ agonist, but is more potent in comparison.[1] WAY-214156 may produce anti-inflammatory effects via the ERβ and has been proposed as a potential treatment for inflammatory conditions such as rheumatoid arthritis.[1][3]

See also

References

  1. ^ a b c d Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC (January 2008). "Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes". Journal of Immunology. 180 (1): 630–636. doi:10.4049/jimmunol.180.1.630. PMID 18097065.
  2. ^ Serock MR, Wells AK, Khalil RA (November 2008). "Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause". Recent Patents on Cardiovascular Drug Discovery. 3 (3): 165–186. doi:10.2174/157489008786263970. PMID 18991792.
  3. ^ Roman-Blas JA, Castañeda S, Cutolo M, Herrero-Beaumont G (November 2010). "Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study". Arthritis Care & Research. 62 (11): 1588–1593. doi:10.1002/acr.20275. PMID 20556817. S2CID 19511497.
Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.